Freeline Therapeutics Holdings PLC (FRLN)

NASDAQ: FRLN · IEX Real-Time Price · USD
0.889
+0.019 (2.18%)
Jun 24, 2022 3:43 PM EDT - Market closed
2.18%
Market Cap 57.54M
Revenue (ttm) n/a
Net Income (ttm) -132.18M
Shares Out 64.73M
EPS (ttm) -3.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,401
Open 0.837
Previous Close 0.870
Day's Range 0.837 - 0.950
52-Week Range 0.650 - 15.400
Beta n/a
Analysts Buy
Price Target 8.50 (+856.2%)
Earnings Date May 16, 2022

About FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201,... [Read more...]

Industry Biotechnology
IPO Date Aug 7, 2020
Employees 235
Stock Exchange NASDAQ
Ticker Symbol FRLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is 8.5, which is an increase of 856.24% from the latest price.

Price Target
$8.5
(856.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemosta...

LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therapy ...

Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen

Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schnei...

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from the ...

Freeline Reports First Quarter 2022 Financial Results and Business Highlights

Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease  on track to deliver 2022 milestones

Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired empl...

Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy

Five abstracts accepted with new research and technology insights and data to further enhance AAV-based gene therapy candidates Five abstracts accepted with new research and technology insights and data...

Freeline Appoints Paul Schneider as Chief Financial Officer

Biotech executive with robust experience in financial and corporate strategy and operational excellence will strengthen the company's leadership team Biotech executive with robust experience in financia...

Freeline Reports Full Year 2021 Financial Results and Business Highlights

Phase 1/2 programs on track in Hemophilia B and Gaucher disease and accelerated in Fabry disease

Freeline Announces Updated Development Plan and Timelines for FLT190 for People with Fabry Disease

Company to progress to second dose cohort in the MARVEL-1 study immediately,

Freeline to Participate in Upcoming Investor Conferences

LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that senior management will participate in the following virtua...

Freeline Closes $26.1 Million Registered Direct Offering of American Depositary Shares

Key shareholder support reinforces management's focus on clinical execution, streamlining the organization and advancing the next stage of research and discovery Key shareholder support reinforces manag...

Freeline Announces $26.1 Million Registered Direct Offering of American Depositary Shares

LONDON, March 11, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated ...

Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B

On track to complete dosing of the first cohort and share initial data by the end of the first half of 2022

Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™

FLT190 well-tolerated with promising early efficacy in Fabry disease including sustained α-Gal A expression up to two years

Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discovery

Stennicke, an industry veteran, will join Freeline to lead the research and advancement of the Company's innovative science and platform technology Stennicke, an industry veteran, will join Freeline to ...

Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated g...

Hot Penny Stocks to Watch Right Now That Are Moving in Premarket

These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Informati...

Other symbols: ATHEPSTV

Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher   disease   Type 1

Freeline To Participate In Conferences During January 2022

LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated g...

Freeline Announces 2022 Corporate Priorities and Guidance

Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline's differentiated platform

Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meetin...

B-AMAZE long-term follow up data demonstrate sustained FIX expression up to 3.5 years; potential for expression levels in the normal range with relatively low vector doses

Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference

LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated g...

Freeline to Participate in Stifel 2021 Virtual Healthcare Conference

LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated g...

Freeline Therapeutics Touts Encouraging Data From Fabry Disease Program

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) gave an update on its investigational Fabry disease treatment FLT190, currently in a Phase 1/2 trial, saying the candidate proved durable in the second ...